SCM
KYMR icon

Suvretta Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Suvretta Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-275,000
Closed -$12M – 101
2025
Q2 		$12M Buy
+275,000
New +$9.47M 0.36% 53
2020
Q4 		– Sell
-110,230
Closed -$3.56M – 116
2020
Q3 		$3.56M Buy
+110,230
New +$3.36M 0.06% 72

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Suvretta Capital Management's KYMR Position: Q3 2025 in Review

Suvretta Capital Management sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 275,000 shares — an estimated $12M sold.

Suvretta Capital Management first reported a position in KYMR in Q3 2020 and held it in 2 quarters. The position peaked at $12M in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Suvretta Capital Management reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Suvretta Capital Management sold 275,000 Kymera Therapeutics shares in Q3 2025, an estimated $12M.
  • Suvretta Capital Management first reported a position in Kymera Therapeutics in Q3 2020 and held it in 2 quarters.
  • Suvretta Capital Management's Kymera Therapeutics position peaked at $12M in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Suvretta Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.